Novo Nordisk is suing Hims & Hers for infringing Wegovy's key patent[1][3]. Hims & Hers offers a cheaper compounded version of Wego for $49 that does not include SNAC's proprietary absorption technology[1]. Novo Nordisk claims that this copy is unauthorized, untested and poses a risk to patients because the active ingredient can be destroyed in the intestines[1][2][3]. The company called the Hims product a "non-authentic imitation" of semaglutide[2]. Hims states that the pill contains the same active ingredient as Wego's, but is not FDA approved for safety, efficacy or quality[2]. A quarter of a year earlier, the FDA warned Hims against misleading advertising of compounded GLP-1 drugs[2]. Following the Hims announcement, Novo Nordisk shares fell by more than 5% to 8%[2][5]. The dispute concerns mass compounding and patent infringement for an oral weight loss formulation[1].